Single-center exploratory study: Evaluation of therapeutic impact GLP-1 a gonist on glucose and lipid metabolism and fatty liver disease in obesity u sing genomic information

Kitamoto Takumi0 个研究点目标入组 50 人开始时间: 2023年10月24日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1) Obese patients with a BMI of 30.0 kg/m2 or higher who have glucose intolerance, dyslipidemia, and fatty liver disease, as defined by the Japan Society for the Study of Obesity
•2) Patients who are at least 18 years old and less than 75 years old at the time of consent
•3) Patients who have been fully informed of the study and who have given written consent of their own free will after sufficient understanding of the study

•Persons who meet any of the following conditions are not eligible
•1) Secondary obesity (symptomatic obesity) 2)Patients with a history of wasting disease or condition (severe infection, invasive surgery, malignancy, severe trauma, hyperthyroidism, etc.) that causes extreme weight loss within the past 6 months from the date of consent
•3) Patients with severe diabetes mellitus with an H bA1c of 10% or higher
•4)Patients with severe hypertension (systolic blood pressure > 180 mmHg)
•5) Patients with severe cardiopulmonary, renal, or hepatic dysfunction that is not an indication for exercise therapy
•6) Patients with serious musculoskeletal disorders that are not indications for exercise therapy
•7) Patients with psychiatric disorders that are difficult to manage
•8) Patients who are pregnant, possibly pregnant, within 28 days postpartum, or lactating
•9) Patients who are unable to obtain written consent or who do not understand the outline or purpose of the study
•10) Other patients who are deemed by the investigator or sub investigator to be unsuitable for the safe conduct of the study

发起方

Kitamoto Takumi